C2-8 – 25 mg

Brand:
Cayman
CAS:
300670-16-0
Storage:
-20
UN-No:
Non-Hazardous - /

C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s = 25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively).{38917} It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington’s disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington’s disease.{38918}  

 

Out of stock

SKU: 21177 - Category:

Description

An inhibitor of polyQ aggregation (IC50s = 25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively); inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington’s disease; reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington’s disease (100 and 200 mg/kg),


Formal name: N-(4-bromophenyl)-3-[[(4-bromophenyl)amino]sulfonyl]-benzamide

Synonyms:  Polyglutamine Aggregation Inhibitor III

Molecular weight: 510.2

CAS: 300670-16-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Neuroscience|Neurodegenerative Disorders|Huntington’s Disease